nach oben

Erschienen in:

10.02.2020 | Statins

Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool

verfasst von: Nirupa J. Raghunathan, Emily C. Zabor, Nassim Anderson, Kevin Oeffinger, Emily S. Tonorezos, Deborah Korenstein

Erschienen in: Journal of Cancer Survivorship | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Childhood, adolescent, and young adult cancer survivors treated with radiation therapy (RT) may be unaware of their high cardiovascular disease (CVD) risk or how to mitigate it. Tools are needed to improve understanding. We developed and pilot-tested a risk communication tool for shared decision-making with survivors regarding CVD risk reduction with statin therapy. We included quantitative and qualitative arms to further tool development and testing.

Methods

The statin risk communication tool was adapted from a previously validated tool. Patients were at increased risk for CVD due to history of chest RT and recruited to usual care and intervention arms. The post-visit survey included Likert-like scales to explore acceptability of the tool, knowledge questions, and a decisional conflict scale. This pilot study used descriptive statistics and was not powered for significance. Semi-structured interviews with intervention arm participants explored shared decision-making processes.

Results

Median participant (n = 46) age was 45. Most intervention patients (22/24, 92%) and 50% (11/22) of controls found statin information acceptable while 31% (7/22) of the control arm selected “not applicable” regarding information acceptability. Most participants were unaware of their personal CVD risk or potential statin side effects. In semi-structured interviews, participants found the tool is helpful to visualize risk and aid conversations.

Conclusions

The risk communication tool was acceptable. Qualitative data suggested the tool improved decisional clarity and comfort.

Implications for Cancer Survivors

Poor knowledge of CVD and statins and poor recall of CVD risk conversation suggest a need to continue to optimize conversations regarding cardiovascular risk and statin therapy.

Nur mit Berechtigung zugänglich

Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2328–38. https://doi.org/10.1200/jco.2008.21.1425.CrossRefPubMedPubMedCentral

Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82. https://doi.org/10.1056/NEJMsa060185.CrossRef

Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743–9.CrossRef

McEniery PT, Dorosti K, Schiavone WA, Pedrick TJ, Sheldon WC. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol. 1987;60(13):1020–4.CrossRef

Kupeli S, Hazirolan T, Varan A, Akata D, Alehan D, Hayran M, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol. 2010;28(6):1025–30. https://doi.org/10.1200/jco.2009.25.2627.CrossRefPubMed

Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol. 2007;25(1):43–9. https://doi.org/10.1200/jco.2006.07.0805.CrossRefPubMed

Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. Jama. 2003;290(21):2831–7. https://doi.org/10.1001/jama.290.21.2831.CrossRefPubMed

Chow EJ, Chen Y, Hudson MM, Feijen EAM, Kremer LC, Border WL, et al. Prediction of ischemic heart disease and stroke in survivors of childhood cancer. J Clin Oncol. 2018;36(1):44–52. https://doi.org/10.1200/jco.2017.74.8673.CrossRefPubMed

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults—a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013, 2014;63(25_PA). https://doi.org/10.1016/j.jacc.2013.11.002.

10.

Lenarczyk M, Su J, Haworth ST, Komorowski R, Fish BL, Migrino RQ, et al. Simvastatin mitigates increases in risk factors for and the occurrence of cardiac disease following 10 Gy total body irradiation. Pharmacol Res Perspect. 2015;3(3):e00145. https://doi.org/10.1002/prp2.145.CrossRefPubMedPubMedCentral

11.

Chotenimitkhun R, D'Agostino R Jr, Lawrence JA, Hamilton CA, Jordan JH, Vasu S, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. 2015;31(3):302–7. https://doi.org/10.1016/j.cjca.2014.11.020.CrossRefPubMed

12.

Marlatt KL, Steinberger J, Rudser KD, Dengel DR, Sadak KT, Lee JL, et al. The effect of atorvastatin on vascular function and structure in young adult survivors of childhood cancer: a randomized, placebo-controlled pilot clinical trial. J Adolesc Young Adult Oncol. 2017. https://doi.org/10.1089/jayao.2017.0075.

13.

Addison D, Lawler PR, Emami H, Janjua SA, Staziaki PV, Hallett TR, et al. Incidental statin use and the risk of stroke or transient ischemic attack after radiotherapy for head and neck cancer. J Stroke. 2018;20(1):71–9. https://doi.org/10.5853/jos.2017.01802.CrossRefPubMedPubMedCentral

14.

Boulet J, Pena J, Hulten EA, Neilan TG, Dragomir A, Freeman C, et al. Statin use and risk of vascular events among cancer patients after radiotherapy to the thorax, head, and neck. J Am Heart Assoc. 2019;8(13):e005996. https://doi.org/10.1161/jaha.117.005996.CrossRefPubMedPubMedCentral

15.

Gamboa CM, Safford MM, Levitan EB, Mann DM, Yun H, Glasser SP, et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014;348(2):108–14. https://doi.org/10.1097/maj.0000000000000292.CrossRefPubMedPubMedCentral

16.

Wong ND, Young D, Zhao Y, Nguyen H, Caballes J, Khan I, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109–18. https://doi.org/10.1016/j.jacl.2016.06.011.CrossRefPubMed

17.

Institute of Medicine Committee on Quality of Health Care in A. Crossing the quality chasm: a new health system for the 21st century. Washington (DC): National Academies Press (US); 2001.

18.

Ancker JS, Senathirajah Y, Kukafka R, Starren JB. Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc. 2006;13(6):608–18. https://doi.org/10.1197/jamia.M2115.CrossRefPubMedPubMedCentral

19.

Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, et al. Evidence-based risk communication: a systematic review. Ann Intern Med. 2014;161(4):270–80. https://doi.org/10.7326/m14-0295.CrossRefPubMed

20.

Mann DM, Ponieman D, Montori VM, Arciniega J, McGinn T. The statin choice decision aid in primary care: a randomized trial. Patient Educ Couns. 2010;80(1):138–40. https://doi.org/10.1016/j.pec.2009.10.008.CrossRefPubMed

21.

Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, et al. Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PloS One. 2016;11(3):e0150205. https://doi.org/10.1371/journal.pone.0150205.CrossRefPubMedPubMedCentral

22.

Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167(10):1076–82. https://doi.org/10.1001/archinte.167.10.1076.CrossRefPubMed

23.

O'Connor AM. Validation of a decisional conflict scale. Med Decis Mak. 1995;15(1):25–30. https://doi.org/10.1177/0272989x9501500105.CrossRef

24.

Selic P, Svab I, Repolusk M, Gucek NK. What factors affect patients’ recall of general practitioners’ advice? BMC Fam Pract. 2011;12:141. https://doi.org/10.1186/1471-2296-12-141.CrossRefPubMedPubMedCentral

25.

Kessels RPC. Patients’ memory for medical information. J R Soc Med. 2003;96(5):219–22.PubMedPubMedCentral

26.

Krosnick JA, Alwin DF. An evaluation of a cognitive theory of response-order effects in survey measurement. Public Opin Q. 1987;51(2):201–19. https://doi.org/10.1086/269029.CrossRef

27.

Egleston BL, Miller SM, Meropol NJ. The impact of misclassification due to survey response fatigue on estimation and identifiability of treatment effects. Stat Med. 2011;30(30):3560–72. https://doi.org/10.1002/sim.4377.CrossRefPubMedPubMedCentral

Titel: Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool
verfasst von: Nirupa J. Raghunathan
Emily C. Zabor
Nassim Anderson
Kevin Oeffinger
Emily S. Tonorezos
Deborah Korenstein
Publikationsdatum: 10.02.2020
Verlag: Springer US
Schlagwort: Statins
Erschienen in: Journal of Cancer Survivorship / Ausgabe 4/2020
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-020-00860-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Quality of life in “chronic” cancer survivors: a meta-analysis

Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy

Functional connectome biotypes of chemotherapy-related cognitive impairment

Breastfeeding practices among childhood cancer survivors

The impact of breast cancer on physical activity from midlife to early older adulthood and predictors of change post-diagnosis

Medical conditions and physical function deficits among multiple primary cancer survivors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie